immun-ops2020

Early nine-month data from a clinical trial suggests a new promising first-line treatment option for patients newly diagnosed with pancreatic cancer.

Atebimetinib combined with modified gemcitabine/nab-paclitaxel shows remarkable survival rates in first-line pancreatic cancer, surpassing standard treatments.

First-Line Atebimetinib Plus mGnP Yields High 9-Month OS Rate in Pancreatic Cancer

Immuneering builds momentum with additional first-line pancreatic cancer data, aims for Phase 3 this year

A Slow and Steady Approach to Pancreatic Cancer Therapy

Changing the Ways We Treat Cancer

A Slow And Steady Approach To Cancer Fighting

The MEK effect on cancer — a slow and steady approach to drug resistance